Related Experiment Video
Updated: Jun 12, 2026
07:09
A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
Published on: July 31, 2012
Expression, purification, and characterization of a functional mutant recombinant human interleukin-2
Mingjun Liu1, Bin Wang, Guirong Sun
1Clinical Immunologic Laboratory, Affiliated Hospital of Medical College Qingdao University, No.16 Jiangsu Road, Qingdao 266003, China. jocklmj@yahoo.com.cn
Protein and Peptide Letters
|June 4, 2010
Summary
Researchers engineered a mutant human interleukin-2 (hIL-2) with identical function to the wild-type. This mutant recombinant hIL-2 was efficiently expressed and purified, showing promise for therapeutic applications.
Area of Science:
- Biotechnology
- Immunology
- Protein Engineering
Background:
- Interleukin-2 (IL-2) is a critical cytokine for immune system regulation.
- Developing stable and functional IL-2 variants is essential for immunotherapy.
Purpose of the Study:
- To generate and characterize a mutant recombinant human interleukin-2 (MhIL-2).
- To assess the functional identity of the engineered MhIL-2 compared to wild-type hIL-2.
Main Methods:
- Site-directed mutagenesis was employed to create the MhIL-2.
- Bacterial expression and purification involved nickel ion chelating chromatography, desalting, thrombin cleavage, and Superdex 75 gel filtration.
- Functional assessment utilized peripheral blood mononuclear cells (PBMCs), CD4+, and CD8+ T cell proliferation assays.
Main Results:
- The His-MhIL-2 was expressed with approximately 90% efficiency in a soluble form.
- Purification strategies yielded a final product with >95% purity.
- The engineered mutant demonstrated identical functional properties to wild-type hIL-2 in T cell proliferation assays.
Conclusions:
- A functionally equivalent mutant human interleukin-2 was successfully generated.
- The optimized expression and purification methods ensure high-purity, active protein.
- This MhIL-2 represents a viable alternative to wild-type hIL-2 for potential therapeutic use.
